R&D News | pharmaphorum

News

Gilead, Arcus say TIGIT combo encouraging in GI cancer

Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy

News

Bayer adds a new life science incubator in China

Bayer’s network of Co.Lab life sciences incubators has expanded once again with the announcement of a new site in Shanghai, China, that will focus on oncology cell and gen

News

BMS extends its position in ADCs with $180m Orum deal

Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Thera

News

EFPIA warns EU reforms will hamstring pharma R&D

A trade organisation representing European pharmaceutical companies warned today that the European Commission’s proposed reforms to pharma legislation could result in the

News

Bayer doubles down on Factor XIa with new phase 3 trial

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixe

News

Drug combos from AZ, Boehringer show promise in CKD

Combination regimens based on SGLT2 inhibitors and two drugs with different mechanisms of action have shown activity in patients with chronic kidney disease (CKD), raising

Gilead, Arcus say TIGIT combo encouraging in GI cancer

Bayer adds a new life science incubator in China

BMS extends its position in ADCs with $180m Orum deal

EFPIA warns EU reforms will hamstring pharma R&D

Bayer doubles down on Factor XIa with new phase 3 trial

Drug combos from AZ, Boehringer show promise in CKD

Sandoz says it is entering "golden decade" in biosimilars

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks